SENS is a medical tech company focused on the design and development of glucose monitoring products designed to help people with diabetes.
Pricetarget wave 2 correction: $3.00
Pricetarget wave 3: $12-24.
The pricetarget of wave 3 will likely be driven by the US FDA approval coming march 2021. Hype will most likely drive the early stages of wave 3. Hopefully...
